Company Introduction

Company introduction

Products
Product Details

MEDIPOST Co., Ltd
M E D I P O S T h a s d e d i c a t e d i ts f o c us o n
biotechnology from its foundation in year 2000
until today, in spite of numerous adversities, rises
and falls within the stem cell area.
As a result, MEDIPOST has become a front-runner in the field of the bio-
pharmaceutical drug not only in Korea but also in the world. MEDIPOST
with its state-of-the-art platform technology has led to the development
and approval of the world’s first allogeneic stem cell therapy product –
CARTISTEM.
MEDIPOST continues its endeavors on clinical development and com-
mercialization of stem cell therapeutics to improve quality of lives of
many patients with intractable diseases not only in Korea, but also in
the global markets.
• ‌Stem Cell Therapy Product (Allogeneic umbilical cord blood-derived
mesenchymal stem cells)
• Approved by MFDS Korea in January, 2012.
CARTISTEM
• ‌Indication: For the treatment of knee articular cartilage defects
in patients with osteoarthritis (ICRS grade IV) as a result of
degenerative disease or repeated trauma.
Representative cord blood bank in Korea. Consistent No. 1 stem cell
technology in Korea.
The hematopoietic stem cells and other types of stem cells in cord
Stem Cell Bank:
blood are stored in cord blood bank and then supplied back when
Cord Blood Bank
transplantation is needed for the treatment of diseases.
The cord blood storage process of MEDIPOST is the current standard
of cord blood banks in Korea and is globally recognized as well.
R&D Pipeline

CEO
Yang, Yoon Sun
Location
21, Daewangpangyo-ro
644beon-gil, Bundang-gu,
Seongnam-si, Gyeonggi-do,
Korea
Homepage
http://www.medi-post.co.kr
Contact
Erica Y Ryu General Manager,
MEDIPOST America, Inc.
Rockville, MD 20850
Tel: +1 301 605 1087
E-mail: erica.ryu@
medipostamerica.com

48 49